Senior scientist, Stanford University School of Medicine
Cariad is a senior scientist in the lab of Holbrook Kohrt at Stanford University. His research focuses on understanding tumor-immune system interactions during cancer onset, progression, and treatment. Using high-dimensional, bioinformatic approaches, he profiles the functional capacity of immune cells during tumorigenesis, searching for novel therapeutic targets and predictive biomarkers to stratify patient populations.
Immunomodulation of Natural Killer Cells
We present findings detailing how stimulation of natural killer (NK) cells within the tumor milieu can influence the efficacy of established antibodies such as rituximab, trastuzumab, and cetuximab. Our work demonstrates how the antitumor efficacy of these mAbs, due in part to antibody-dependent cell-mediated cytotoxicity (ADCC), can be enhanced by stimulation of NK cells with an anti-CD137 agonistic mAb.